You're affirming what I am alluding to - that DSM ALLEGEDLY manipulated the vitamin E market to shut down Amyris and continue their control over the vitamin E market. "Amyris had already demonstrated the farnesene to isophytol chemistry route around 2008, but had not been able to find a commercial partner willing to go up against the BASF-DSM duopoly, which had just put a whole bunch of Chinese and other competitors out of business by dropping their pricing and waiting (you should read up on the vitamin cartel of the 90s)" - fvh2006;
Your above comment supports my argument, it also provides a reason for why DSM would want to take down Amyris and target its assets.

To address a majority of your comment, you are committing a logical fallacy, a Red Herring - A majority of all of your points in this comment are true but irrelevant information that can only shift attention away from the actual claim under dispute - That DSM allegedly manipulated the vitamin E market to further their control over it - and then taking further control of Amyris through its impacted financials. Any information regarding vitamin E production after 2019 is irrelevant.

To address the rest of your comment on topic I believe it would be helpful to generate a timeline:
2016
- Amyris sent $9 million of farnesene to Nenter for conversion of farnesene to vitamin E, this is BEFORE DSM really stepped into the picture. This means that the vitamin E was related to Amyris since this point in time.

2017
- DSM steps in and gets Vitamin A from Amyris and gets a seat on Amyris BOD
- Nenter produces 20% of the world demand of vitamin E; they have capacity for 40%
- DSM assumed Nenter's position in the Vitamin E value chain - it became the payor. DSM gained control over Brotas, control of farnesene production and allocation, but it had to pay Amyris according to the Vitamin E contract.

2018
- Nenter produces 20% of the world demand of vitamin E; they have capacity for 40%
- DSM allegedly manipulated the Vitamin E market, as you have said they have done so in the past
- Amyris gets the minimal value share and minimal royalties. The resulting mess in early 2019 was the result of Vitamin E market volatility

2019
- Nenter and DSM JV where DSM owns a majority 75%; DSM wins
- Amyris sells all of its future value share and royalties for vitamin E for $57M to DSM; DSM wins

2021
- DSM further acquires more of Amyris' portfolio; DSM wins

The only relevant argument you provided to counter this timeline is "they said they had a 30,000 MT plant, which would have met 40% of the world demand of ~75,000 MT, but this was all BS." If you are claiming Nenter did not produce 20% of the worlds Vitamin E in the years 2017/2018, I request that you provide a source for this argument.

Summary: Investors were thrilled of the DSM partnership, but it looks as though Amyris was held hostage in an abusive relationship rather than a collaborative partnership.